Although the clinical efficacy of everolimus has been demonstrated in HR-positive and HER2-positive breast cancers, the benefits may be more pronounced in selected subsets rather than the overall population, as seen in the BOLERO and TAMRAD studies. The gene discussed is ERBB2; the disease is breast carcinoma.